单细胞解析揭示 CD5 或 CD7 靶向 CAR-T 细胞治疗后的免疫失调
Single-Cell Dissection Reveals Immune Dysregulation After CD5 or CD7-Directed Chimeric Antigen Receptor T-Cell Therapy.
74.1分
★★★★☆
站内排序·非疗效
FRONTIER PAPERS
Single-Cell Dissection Reveals Immune Dysregulation After CD5 or CD7-Directed Chimeric Antigen Receptor T-Cell Therapy.
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法,CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。
共 3 条
MEMBER ACCOUNT
登录成功会直接打开下一页。